|1.||Skwarska, Anna: 4 articles (06/2015 - 12/2007)|
|2.||Augustin, Ewa: 4 articles (06/2015 - 12/2007)|
|3.||Konopa, Jerzy: 4 articles (09/2013 - 03/2005)|
|4.||Polewska, Joanna: 3 articles (06/2015 - 02/2013)|
|5.||Mazerska, Zofia: 2 articles (02/2013 - 09/2012)|
|6.||Peters, G J: 2 articles (07/2011 - 05/2009)|
|7.||Mayur, Y C: 2 articles (07/2011 - 05/2009)|
|8.||Beffinger, Michał: 1 article (06/2015)|
|9.||Laskowska, Katarzyna: 1 article (06/2015)|
|10.||Konicz, Sonia: 1 article (06/2015)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
09/01/1999 - "C1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into clinical trial. "
10/01/2007 - "The aim of this study was to investigate the antiproliferative effects of C-1311 (Symadex), a member of the imidazoacridinone family, in human colorectal cancer cells. "
03/15/2001 - "The imidazoacridinone derivative, C-1311, is a new antitumour agent that exhibits strong antitumour activity against experimental colorectal cancer and has been selected for entry into clinical trial. "
|2.||Breast Neoplasms (Breast Cancer)
06/15/2015 - "RNA interference against FLT3-ITD reduced cytotoxic effect and apoptosis induced by C-1311, indicating selective inhibition of FLT3-ITD crucial for high efficacy of drug against activated leukemia cells. "
12/01/2007 - "Here, we elucidated the sequence of death responses to C-1311 in human leukemia MOLT4 cells using drug concentration (30 nM) that causes near complete cell growth inhibition at 48 h. "
12/01/2007 - "Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311."
06/15/2015 - "Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells."
07/17/2011 - "The in vitro cytotoxic effects in comparison with reference drugs doxorubicin (DX) and C(1311) against cancer cell lines SW 1573, SW 1573 2R 160 (Pg-P expressing) which are non-small cell lung cancer cells, human embryo kidney cells HEK 293, HEK 293 MRP4, HEK 293 MRP5i, human promyelocytic leukemia sensitive cell line HL-60, including its multidrug cross-resistant of two main (P-gp and MRP) phenotype sublines vincristine resistant HL-60/VINC and doxorubicin resistant HL-60/DX cancer cell lines are presented. "
02/01/1999 - "Preliminary in vitro toxicity studies showed M2 to be as potent as C1311 against MAC15A tumor cells. "
02/01/1999 - "Previous murine pharmacokinetic studies have shown C1311 to be rapidly and extensively distributed into tissues including tumor. "
03/01/2005 - "C1311 is the lead compound from the imidazoacridinones, a novel group of rationally designed anti-cancer agents. "
03/01/2005 - "Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility."
01/01/2011 - "Coupling COXEN and yeast chemigenomics provides rational combinations with C1311 and tumor genomic signatures that can be used to select bladder cancer patients for clinical trials with this agent."
03/01/2005 - "In this study, we investigated the cell death process induced by imidazoacridone C-1311 (Symadex) in HT-29 human colon carcinoma cells which have been shown to be preferentially sensitive to this compound in experimental tumour models both in vitro and in nude mice. "
03/01/2005 - "Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells."
09/01/1999 - "The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase II. In this study, cellular uptake and mechanisms by which C1311 interacts with DNA and exerts cytotoxic effects in intact colon carcinoma cells were investigated. "
|1.||DNA (Deoxyribonucleic Acid)
|2.||Type II DNA Topoisomerases (Topoisomerase II)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)